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1.  Introduction 
 
1.1 Traumatic Brain Injury 
 
Traumatic Brain Injury (TBI) is an alteration of brain pathology following damage of the 
central nervous system (CNS) by an external force [1]. In the United States, approximately 2.8 
million Americans sustain a TBI annually with numbers increasing over the last several years. 
Elderly (≥75 years), children (0-4 years) and young adults (15-24 years) account for the majority 
of TBI Emergency department visits, hospitalizations, and deaths in the U.S. [2]. Particularly 
concerning, TBI remains the leading cause of death among infants and children [3-4]. With the 
prevalence of TBI increasing, research into the mechanics of tissue degeneration and 
preservation following TBI is warranted. Through increased understanding of cellular response 
to TBI, targeted therapies and treatment strategies to promote neural function regeneration can 
be explored.  
 
1.2 The Roles of Astrocytes 
 
In the central nervous system (CNS), glial scar formation often occurs following TBI, and 
astrocytes are widely believed to contribute to this scar formation.  The role of glial scar 
formation in TBI is not completely understood. However, it is widely believed it performs both 
positive and negative functions. The barrier created by the glial scar walls off damaged tissue to 
limit cellular inflammation and degeneration. A secondary effect of this barrier formation is 
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blocking of axonal regeneration of the area preventing functional regeneration [5-6]. Following 
TBI and other CNS insults, astrocytes are known to react in a process known as reactive gliosis. 
Astrocytes are a specialized structure and support cells found in both injured and uninjured CNS 
responsible for many essential, non-neurotransmission functions [7-8]. Of particular interest to 
this research is the role astrocytes play in extracellular matrix (ECM) production. While the exact 
composition of ECM varies among tissue types and hosts, it is generally composed of protein 
fibers including collagen, glycoproteins, and proteoglycans in a hydrated gel (8). During reactive 
gliosis, astrocytes congregate around the damaged area and ECM composition is altered (Figure 
1) [6]. While the role of astrocytes in ECM production is known, the exact mechanism(s) for this 







1.3 Transient Receptor Potential Vanilloid 4 
  
 One possible component to this mechanism is the activation of transient receptor 
potential vanilloid 4 (TRPV4). TRPV4 is a non-specific ion channel permeable to calcium ions, 
and is found in a diverse array of tissues throughout the body. TRPV4 activation is achieved 
through a variety of stimuli including osmolality and mechanotransduction among others [9-
12]. O’Conor et al has shown activation of TRPV4 to increase collagen content in chondrocytes 
following mechanical loading [10]. Similar mechanical stimuli in TBI may result in similar TRPV4 
activation in astrocytes and subsequent increase in collagen levels in glial scar formation. 
GSK1016790A, a known TRPV4 agonist, and GSK 205, a known TRPV4 antagonist offer one 
method for TRPV4 activation/inactivation research [10-13]. As a potential activator of astrocyte 
ECM production, TRPV4 represents a possible link between TBI and glial scar formation. The 
goal of this study was to compare mouse astrocyte matrix composition and mechanical 
properties following TRPV4 biochemical activation/inactivation through rheological analysis 
techniques.  
 
2. Materials and Methods 
 
2.1 Cell Culture 
 
 Frozen vials of C8-D1A mouse astrocyte clones were thawed in a 37˚C water bath and 
added to 7 mL of warmed DMEM supplemented media in a T75 flask. DMEM media was 
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supplemented with 10% FBS, 1% L-Glutamine, and 1% Penicillin/Streptomycin throughout 
experiment. Media was replaced every 48 hours with fresh media until 80-90 percent confluency 
was reached. Cells were then split into two T175 flasks. Media was aspirated, 7 mL trypsin EDTA 
was added, and flask was incubated until cell detachment was observed. Media (7 mL) was added 
to neutralized trypsin, and the resulting 14 mL cell solution was collected and centrifuged at 300 
G for 10 minutes. Supernatant was aspirated and cell pellet was resuspended in 4 mL media 
before being evenly distributed between two T175 flasks containing 12 mL warmed media. This 
process was continued until confluence was reached.  
 
2.2 Gel Mold and Well Preparation 
  
 Gel molds were fabricated from 1/8” thick high temperature super-soft silicone rubber 
sheet (McMaster-Carr) and 22 mm diameter glass coverslips (VWR). Silicone sheeting was cut 
into circular mold rings with 3/4” outer diameter and 3/8” inner diameter. Silicone rings and 
coverslips were washed and sonicated in 70% ethanol for 20 minutes. Following sonication, 
coverslips were gently pressed onto silicone rings forming the molds (Figure 2). Completed molds 
were then sterilized in an autoclave. All molds were placed coverslip side down into sterile 





Figure 2: Transwell plates (A) containing silicone molds (B) used to house, grow, and 
transfer mouse astrocyte gels over the course of experiment. Gels were submerged in 
supplemented media (C) throughout experiment. Following experiment, gels were 
removed from molds (D). Gels present only in first three wells. 
 
 Confluent cells were removed from T175 flasks as previously described in 2.1 and counted 
using a hemocytometer. Following counting, desired cell volume was centrifuged at 300 G for 10 
minutes, media was aspirated, and cells were resuspended in cold Matrigel (Corning). 
Cell/Matrigel suspension was seeded into molds at a concentration of 500,000 cells per mold 
(300 μL Matrigel). Plates were incubated at 37˚C for 30 minutes until gelation occurred. 5 mL 
media was then added to each well ensuring molds were completely submerged. Gels were 
incubated for 48 hours prior to first treatment. Media was replaced every 48 hours until 







2.3 Astrocyte Sample Treatment 
 
 Astrocyte seeded gels were exposed of to one of three treatments – no treatment control, 
TRPV4 agonist, or TRPV4 antagonist – over the course of three weeks with six gels per treatment 
group. Control treatment media contained normal supplements with added trace amounts of 
DMSO consistent with DMSO concentrations in alternate treatments. TRPV4 agonist media 
contained 1μM GSK1016790A (Sigma-Aldrich). TRPV4 antagonist media contained 100μM 
GSK205 (EMD Millipore). Treatments were diluted to desired concentration through a series of 
dilution steps. Treatment media was added to six well plates and transwells containing astrocyte 
seeded gels were transferred to wells containing respective treatment media. Gels were 
submerged and incubated for 30 minutes at which time transwells and gels were returned to 
original plate containing fresh, non-treated media. This process was repeated every 48 hours 
over the course of three weeks.  
 
2.4 Astrocyte Viability Testing 
 
 Cell viability was testing using Molecular Probes™ Invitrogen detection technologies 
Live/Dead® Viability/Cytotoxicity Kit for mammalian cells.  Reagent stock solutions were warmed 
to room temperature. 20 μL EthD-1 stock solution was added to 10 μL sterile PBS and vortexed 
to ensure proper mixing. 5 μL calcien-AM stock solution was added to the 10 µL EthD-1 solution 
and vortexed to ensure proper mixing. Astrocyte seeded gels in molds were prepared prior to the 
assay with two rinses of sterile PBS. 150 µL prepared reagent solution was added to prepared 
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cells and incubated, while covered, at room temperature for 45 minutes. One gel per treatment 
group was tested. Following incubation, cover slips were placed over top of molds, and cells were 
visualized and imaged under fluorescence microscope at 4X magnification.  
 
2.5 Gel Rheological Testing 
 
 Following treatments, gel mechanical properties were tested using a Discovery HR-2 
rheometer with 10 mm parallel plate attachments (Figure 3A). Gels were removed from molds 
just prior to treatment by first removing the coverslip then excising gels from silicone molds using 
a 15-mm biopsy punch. The rheometer inertia, friction, and rotational mapping were calibrated.  
Gels were then positioned on the bottom rheometer plate warmed to 37˚C, and the plate gap 
was set to 1500 μm. This gap and temperature were used for all samples. Drops of 1X PBS solution 
were placed around sample to prevent dehydration during testing (Figure 3B). A frequency sweep 
from 0.1 - 100 hertz was performed on a log scale with five points per decade and at a strain of 
10%. Frequency, storage modulus, and loss modulus data was collected for each sample. 
Rheometer plates were cleaned with 70% ethanol and allowed to dry between tests. After test 
completion, each sample was stored in a 1.5 mL microcentrifuge tube at -80˚C for additional 




Figure 3: Discovery HR-2 rheometer with 10 mm parallel plate attachments and heated 




2.6 Statistical Analysis 
 
 Treatment groups were compared using a oneway ANOVA and Tukey-Kramer HSD. 
Acceptance criteria for statistical significance required p values less than 0.05. Storage modulus 
(G’) and loss modulus (G’’) data at 1 hertz were used for comparison as this frequency most 










 Cell viability testing was performed prior to rheological testing to ensure cells had 
survived during three-week treatment period. Each treatment group sample showed similar 
levels of viable cell density (qualitative) with no staining of dead cells visible (Figure 4). Cells 
appeared to be dispersed across all planes within the gel.  
 
 
Figure 4: EthD-1 staining of astrocyte seeded gel post treatments at 4X magnification. 
Dark region (lower left) corresponds to inner edge of silicone mold. Calcien-AM staining 
(not imaged) was negligible. 
 
 
 Rheological testing data showed exponential increased in storage modulus with increased 
frequency with similar trends across all treatment groups. Loss modulus showed no discernable 




Figure 5: Sample representation of storage modulus and loss modulus frequency 
sweeps from 0.1-100 hertz for control, agonist, and antagonist treatments 
 
At one hertz, storage modulus mean values of control, agonist, and antagonist treatment 
groups were 147.503 Pa, 184.468 Pa, and 176.845 Pa respectively. Agonist storage modulus was 
significantly higher as compared to control (p=0.0422). While not statistically significant 
(p=0.1139), antagonist treatment showed an increase in storage modulus as compared to 
control, as well (Figure 6A). Loss modulus mean values of control, agonist, and antagonist 
treatment groups at one hertz were 17.686 Pa, 22.685 Pa, and 19.108 Pa respectively. Loss 




Figure 6: Mean storage modulus (A) and loss modulus values for control, agonist, and 
antagonist samples at 1 Hz in parallel plate rheometer frequency sweep.  Storage 
modulus was found to have increase significantly (*) in agonist treated samples as 
compared to control. 
 
4. Discussion and Conclusion 
 
 Matrigel in silicone and glass molds provided a suitable growth environment for mouse 
astrocytes throughout treatments as demonstrated by negligible cell death after three weeks. 
Further cell quantification methods are required to determine magnitude of cell growth during 
this period. Previous research has confirmed TRPV4 gene expression in these cells.  
 Storage modulus data corresponds to elastic properties of the samples while loss modulus 
data corresponds to viscous properties of the samples. Storage modulus data was significantly 
higher than loss modulus data showing the astrocyte seeded gels possessed mostly elastic 
properties. When the agonist protein, 10 μM GSK 101, was introduced, treated samples displayed 
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a higher mean storage modulus value as compared to control samples. There are many possible 
sources for this change, however one explanation would be an increase in collagen deposition as 
collagen displays primarily elastic properties [11]. This would suggest that activation of TRPV4 
plays a role in astrocyte ECM production, specifically collagen production. The increase in 
collagen levels will be confirmed in subsequent research including hydroxyproline assay studies 
of samples. As the mean value storage modulus data also increased for the antagonist treatment 
group, although not significantly, there likely exists a more complex relationship between TRPV4 
activation and astrocyte ECM production that warrants further studies and analysis. 
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